SIRT1 and systemic lupus erythematosus: Animal studies. Using in vivo assays to test if resveratrol, a well-known SIRT1 activator, may be useful for SLE treatment, Wang and collaborators (2014) used a pristane-induced lupus BALB/c mouse model [119], in which the mice received an 0.5 mL injection of pristane and were treated with resveratrol (50 mg/kg/day and 75 mg/kg/day) over 7 months and the serum levels of autoantibodies and kidney damage were assessed [115].